EAM provides a dynamic platform for fostering interdisciplinary collaboration among the world’s leading medical experts. Through its Collaborative Networks, EAM facilitates seamless partnerships across specialties and institutions, driving global advancements in medical science.

• Interdisciplinary Collaboration Across Specialties;
• Access to Global Research and Resources;
• Engagement with Policymakers and Industry Leaders;
• Global Recognition and Influence.

The European Academy of Medical Sciences (EAM) is a globally recognized institution that fosters collaboration among the world’s leading medical experts, researchers, and healthcare professionals. EAM’s Collaborative Networks are at the heart of its mission to advance medical science by enabling interdisciplinary partnerships that transcend geographic, cultural, and disciplinary boundaries. By leveraging the collective expertise of its diverse membership, EAM creates an environment where the brightest minds in medicine can work together to address the most pressing healthcare challenges of our time.

One of the key benefits of EAM’s Collaborative Networks is the opportunity for researchers and clinicians to connect with peers from a wide range of specialties. The Academy brings together experts in fields such as pharmacology, immunology, virology, neuroscience, public health, and clinical medicine, fostering a multidisciplinary approach to research and innovation. This interdisciplinary collaboration is crucial in today’s complex medical landscape, where advances in one field often depend on insights from another. By facilitating these cross-disciplinary connections, EAM ensures that its members can collaborate effectively, driving forward new ideas and solutions that might not emerge within the confines of a single discipline.

EAM’s networks also provide access to cutting-edge research, data, and resources. Members benefit from collaborative research projects, joint publications, and the sharing of data across institutions and countries. These partnerships are particularly important in the context of large-scale studies and clinical trials, where pooling resources and expertise can significantly accelerate the pace of discovery. Through its extensive global network, EAM facilitates partnerships between academic institutions, research organizations, and healthcare enterprises, ensuring that groundbreaking research can be translated into practical applications with real-world impact.

EAM’s Collaborative Networks extend beyond the realm of scientific research. The Academy plays a key role in connecting its members with policymakers, industry leaders, and public health organizations, allowing for the exchange of knowledge and the development of evidence-based health policies. By fostering dialogue between scientists and decision-makers, EAM ensures that the latest scientific discoveries are effectively translated into policies that improve global health outcomes. This engagement with both the scientific and policy communities enhances the real-world impact of members' research and elevates their professional standing within the global medical community.

EAM Member Sections

The European Academy of Medical Sciences (EAM) is dedicated to advancing global health through its Research and Innovation Platforms, which serve as a catalyst for groundbreaking discoveries and advancements in medical science. These platforms are designed to foster cutting-edge research, interdisciplinary collaboration, and the translation of scientific breakthroughs into real-world medical applications. By bringing together leading experts, research institutions, and healthcare organizations, EAM creates an environment where innovation can flourish, driving forward the frontiers of medicine.

Promoting Collaborative Research
At the heart of EAM’s Research and Innovation Platforms is the promotion of collaborative research across various disciplines and regions. EAM connects top-tier scientists, clinicians, and researchers from different fields, encouraging the cross-pollination of ideas that lead to innovative solutions. This interdisciplinary approach is essential for tackling complex healthcare challenges, such as emerging diseases, aging populations, and chronic illnesses. Through joint research initiatives, EAM members engage in high-impact projects that address these critical issues, often resulting in groundbreaking discoveries that advance the field of medical science.

Supporting Translational Medicine
EAM’s Research and Innovation Platforms also prioritize translational medicine, the process of turning basic scientific research into clinical applications that improve patient care. By supporting research that bridges the gap between laboratory discoveries and clinical implementation, EAM ensures that its members’ work has a direct and positive impact on healthcare outcomes. The platforms provide resources and guidance for researchers looking to move their findings from the bench to bedside, accelerating the development of new treatments, therapies, and medical technologies.

Fostering Innovation in Healthcare Technologies
Innovation is a core component of EAM’s mission, and its platforms play a key role in driving technological advancements in healthcare. From artificial intelligence and machine learning applications in diagnostics to the development of cutting-edge medical devices and pharmaceutical innovations, EAM’s platforms are at the forefront of integrating new technologies into the medical field. By fostering partnerships between researchers, technology companies, and healthcare providers, EAM ensures that innovations are not only scientifically sound but also practically applicable in improving patient care.

Global Impact and Policy Influence
EAM’s Research and Innovation Platforms extend beyond the laboratory and clinical settings. The Academy actively engages with global health policymakers to ensure that research findings inform public health strategies and medical regulations. Through its research initiatives, EAM influences health policies that shape the future of healthcare, making the Academy a vital player in global health governance.

EAM’s Research and Innovation Platforms provide a robust framework for collaborative research, support the translation of discoveries into clinical practice, foster technological innovation, and influence global health policy, ensuring that the Academy remains at the cutting edge of medical science.

The European Academy of Medical Sciences (EAM) plays a critical role in shaping global health policies through its rigorous, evidence-based contributions to the development of public health strategies, medical regulations, and healthcare reforms. EAM’s Policy Impact efforts are grounded in its commitment to advancing medical science and improving population health outcomes. By leveraging the collective expertise of its members—comprised of world-leading medical researchers, clinicians, and public health experts—EAM provides authoritative guidance to governments, international organizations, and industry leaders on the most pressing health challenges of our time.

Evidence-Based Policy Recommendations
At the core of EAM’s policy impact is its ability to translate scientific research into actionable policy recommendations. EAM’s members are engaged in cutting-edge research across a wide range of medical fields, from epidemiology and infectious diseases to chronic illness and mental health. By synthesizing the latest research findings and drawing upon interdisciplinary insights, EAM formulates policy guidance that addresses both current and emerging health threats. The Academy’s recommendations are based on the highest standards of scientific rigor, ensuring that policymakers receive accurate and timely advice that can guide effective decision-making.

Influencing Global Health Governance
EAM’s influence extends to the international stage, where it works closely with global health bodies such as the World Health Organization (WHO), the European Union (EU), and national governments to shape healthcare policies that are responsive to global challenges. Through its engagement with these institutions, EAM advocates for policies that prioritize scientific evidence, equity in healthcare, and the promotion of public health. The Academy’s contributions to global health governance are aimed at ensuring that research-backed solutions are implemented at the highest levels of policy, resulting in meaningful improvements in health outcomes worldwide.

Bridging the Gap Between Science and Policy
A key strength of EAM is its ability to bridge the often significant gap between scientific discovery and policy implementation. While many groundbreaking medical advancements remain confined to the research community, EAM actively works to bring these innovations into the public policy domain. By engaging with policymakers, EAM ensures that the latest scientific insights are integrated into healthcare legislation and public health programs. This approach enables policymakers to make informed decisions that reflect the most current scientific understanding, leading to better healthcare systems and healthier populations.

Advising on Emerging Health Challenges
In addition to its work on established health concerns, EAM plays a proactive role in advising on emerging and unforeseen health challenges. From global pandemics to the impact of climate change on health, the Academy provides critical insight into how these evolving issues should be addressed through evidence-based policies. EAM’s expert-driven approach ensures that its policy recommendations are forward-looking, equipping policymakers with the tools they need to respond effectively to future healthcare challenges.

The European Academy of Medical Sciences (EAM) is deeply committed to fostering the growth and development of medical professionals, scientists, and healthcare leaders through its comprehensive Educational and Developmental Resources. These resources are designed to equip the next generation of medical professionals with the knowledge, skills, and tools necessary to drive forward innovations in healthcare and contribute to the advancement of global health. EAM’s educational initiatives are grounded in academic excellence, ensuring that participants receive the highest quality training and professional development opportunities.

Advanced Educational Programs
EAM offers a range of advanced educational programs that cater to professionals at all stages of their careers. From early-career researchers and clinicians to established leaders in medicine, the Academy provides tailored learning experiences that reflect the latest developments in medical science and healthcare practice. These programs include workshops, seminars, and masterclasses led by some of the world’s most respected medical experts. EAM’s educational offerings emphasize both theoretical knowledge and practical application, ensuring that participants can directly implement what they have learned in their own professional contexts.

One of the Academy’s key initiatives is the development of specialized curricula that address emerging trends and challenges in healthcare. Topics such as personalized medicine, artificial intelligence in healthcare, and global health security are integrated into EAM’s educational frameworks, keeping participants at the forefront of medical innovation. By engaging with these cutting-edge subjects, medical professionals gain a deep understanding of the future landscape of healthcare and are better prepared to lead in their respective fields.

Professional Development and Mentorship
In addition to formal educational programs, EAM provides robust professional development opportunities that help medical professionals enhance their skills and advance their careers. The Academy’s mentorship initiatives are particularly noteworthy, as they connect early-career researchers and clinicians with established leaders in the medical field. These mentorship programs are designed to foster intellectual growth, provide career guidance, and promote networking opportunities that can lead to collaborative research and professional partnerships.

EAM’s mentorship efforts extend beyond the academic and clinical realms to include leadership training and skills development. Recognizing the importance of leadership in advancing healthcare, the Academy offers workshops on management, communication, and strategic planning, which are essential for professionals aspiring to leadership positions within their institutions or the broader medical community.

Lifelong Learning and Continuing Education
As the medical field evolves, so too must the professionals within it. EAM is dedicated to the concept of lifelong learning, ensuring that its members and participants remain current with the latest developments in their areas of expertise. The Academy offers continuing education programs that are specifically designed to help medical professionals stay up-to-date with emerging research, new medical technologies, and best practices in patient care. These programs are accredited and recognized internationally, making them valuable credentials for career advancement.

EAM’s commitment to education extends globally, with online platforms that provide access to educational materials and resources to members across the world. This ensures that medical professionals, regardless of geographic location, can benefit from the Academy’s expertise and knowledge base.

Detailed Introduction
Sir James Black was born in Uddingston, Scotland, in 1924. His early academic path was shaped by a passion for both science and medicine. He graduated with a degree in medicine from the University of St. Andrews in 1946. Although trained as a physician, Black’s interests leaned more toward medical research, leading him to pursue a career in pharmacology. He believed that understanding the mechanisms behind diseases could enable the development of more effective treatments—an approach that would come to define his illustrious career.

Black’s career began in earnest at the University of Glasgow, where he worked on developing methods to measure blood flow in peripheral tissues. However, his major breakthroughs occurred later, during his time at ICI Pharmaceuticals and Smith, Kline & French Laboratories, where his work would fundamentally change modern pharmacology.

The Discovery of Beta-Blockers
Sir James Black is perhaps most renowned for his development of the first beta-blocker, propranolol. In the 1950s, while working at ICI Pharmaceuticals, Black theorized that blocking the effects of adrenaline on the heart could help manage conditions such as angina and arrhythmias. This was a revolutionary concept at the time, as it marked a shift away from the prevailing method of treating cardiovascular conditions by dilating blood vessels or altering heart rhythm. Black instead targeted the beta-adrenergic receptors responsible for regulating the heart’s response to stress hormones like adrenaline.

The development of propranolol in 1964 represented a major milestone in cardiovascular medicine. Propranolol was the first drug of its kind to successfully block the effects of adrenaline on the heart, reducing heart rate and blood pressure in patients suffering from angina. The drug quickly became a standard treatment for a range of cardiovascular conditions and is widely regarded as one of the most important therapeutic advancements of the 20th century.

H2 Receptor Antagonists and Gastric Acid
Building on his success with beta-blockers, Sir James Black turned his attention to the problem of peptic ulcers, which were believed to be caused by excessive stomach acid production. At Smith, Kline & French Laboratories, he developed cimetidine, the first H2 receptor antagonist, in the 1970s. By blocking the histamine H2 receptors in the stomach, cimetidine dramatically reduced acid production and provided relief for patients suffering from ulcers. It was the first drug to specifically target the underlying cause of ulcers rather than just treating symptoms, and its development revolutionized gastroenterology.

Cimetidine’s success was swift and profound, becoming one of the first “blockbuster” drugs in medical history. It significantly improved the quality of life for millions of ulcer sufferers and set the stage for future developments in the treatment of gastrointestinal diseases.

Legacy and Honors
Sir James Black’s contributions to medicine were widely recognized throughout his lifetime. In addition to receiving the Nobel Prize in Physiology or Medicine in 1988, Black was knighted by Queen Elizabeth II in 1981 for his services to medicine. He also received numerous prestigious awards, including the Lasker Award, the Royal Medal, and the Cameron Prize for Therapeutics of the University of Edinburgh.

Beyond his scientific discoveries, Black was known for his humility and his deep commitment to mentorship. He spent the latter part of his career in academia, holding professorial roles at King’s College London and the University of Dundee, where he nurtured the next generation of medical scientists.

Sir James Black’s legacy is a testament to the power of innovative thinking in medical science. His pioneering research into beta-blockers and H2 receptor antagonists continues to shape modern pharmacology, improving the lives of millions of patients worldwide. Black’s ability to combine scientific rigor with clinical insight made him one of the most influential figures in 20th-century medicine. His contributions not only transformed therapeutic strategies but also set new standards for how pharmacological research could directly benefit human health.

Detailed Introduction
Jean-Baptiste-Gabriel-Joachim Dausset was born in Toulouse, France, in 1916. His early academic interests in biology and medicine led him to study at the University of Paris, where he earned his medical degree in 1945. After serving as a medical officer in World War II, Dausset returned to Paris, where he began a career in research that would ultimately redefine the field of immunology. His early work focused on blood diseases and the body's immune response to foreign substances, which laid the groundwork for his later revolutionary discoveries.

The Discovery of the Human Leukocyte Antigen (HLA) System
Jean Dausset is best known for his discovery of the HLA system, a group of proteins found on the surface of white blood cells (leukocytes) that play a crucial role in the body’s immune response. In the early 1950s, while working at the National Blood Transfusion Center in Paris, Dausset observed that certain blood transfusions caused severe immune reactions in recipients. These reactions were later attributed to the presence of specific antigens, which Dausset identified as part of the HLA system.

Through meticulous research, Dausset discovered that the HLA proteins are responsible for regulating the immune system’s ability to distinguish between self and non-self. This breakthrough provided the first clear understanding of how the immune system recognizes foreign tissue and triggers immune responses, an insight that was vital to the development of successful organ transplantation.

Before Dausset's discovery, organ transplants were fraught with complications due to immune rejection, as the body often identified transplanted tissue as foreign and attacked it. The HLA system provided the key to matching donors and recipients based on immune compatibility, dramatically increasing the success rates of organ transplants and paving the way for the field of transplant medicine as we know it today.

Impact on Transplantation and Autoimmune Diseases
The discovery of the HLA system not only revolutionized organ transplantation but also had far-reaching implications for understanding autoimmune diseases, in which the immune system mistakenly attacks the body’s own tissues. Dausset’s work allowed researchers to explore the genetic basis of these conditions, leading to advances in the diagnosis and treatment of diseases such as rheumatoid arthritis, multiple sclerosis, and type 1 diabetes.

Furthermore, the HLA system plays a pivotal role in the field of bone marrow transplantation, where it is critical to match donors and recipients based on HLA compatibility to prevent graft-versus-host disease. The development of HLA typing techniques, which are now routine in transplant medicine, has enabled life-saving transplants for patients with leukemia and other hematological disorders.

Legacy and Honors
Jean Dausset’s contributions to science were recognized with numerous prestigious awards throughout his career. In addition to receiving the Nobel Prize in Physiology or Medicine in 1980, Dausset was elected to the French Academy of Sciences and was awarded the Grand Cross of the Legion of Honor, one of France’s highest distinctions. He was also instrumental in founding the National Institute of Health and Medical Research (INSERM) in France, where he worked to promote biomedical research and the development of new medical technologies.

Dausset’s legacy extends beyond his scientific discoveries; he was also a dedicated mentor and advocate for scientific collaboration. He established the Foundation Jean Dausset–CEPH, an international genetic research center focused on understanding the human genome and its relation to disease. Through this foundation, Dausset supported groundbreaking research in genetics and immunology, ensuring that his contributions to science would continue to benefit future generations.

Jean Dausset’s discovery of the HLA system transformed the field of immunology and organ transplantation, saving countless lives and improving the quality of medical care worldwide. His pioneering research into immune compatibility remains a cornerstone of modern medicine, and his impact on the fields of transplantation, autoimmune diseases, and genetics continues to be felt today. As one of the leading figures in medical science, Jean Dausset’s work exemplifies the profound influence that scientific research can have on human health and well-being.

Detailed Introduction
Born in Turin, Italy, in 1909, Rita Levi-Montalcini pursued a medical degree at the University of Turin, where she studied under prominent histologist Giuseppe Levi. Despite facing discrimination and significant professional obstacles due to her gender and Jewish heritage, Levi-Montalcini’s passion for science and determination to understand the human body drove her to pursue a career in neurobiology. Following the enactment of anti-Jewish laws by the Italian fascist regime in 1938, Levi-Montalcini was barred from academic work and was forced to conduct her research from a makeshift laboratory in her bedroom. It was during these difficult years that she laid the groundwork for the research that would later transform the field of neuroscience.

Discovery of Nerve Growth Factor (NGF)
Rita Levi-Montalcini is best known for her discovery of nerve growth factor (NGF), a protein that plays a critical role in the growth, maintenance, and survival of nerve cells, or neurons. Her initial research in the 1940s involved studying the development of nerve fibers in chicken embryos. She observed that certain cells were able to stimulate nerve growth, leading to the formation of neurons. Through a series of meticulous experiments, Levi-Montalcini identified NGF as the factor responsible for this process.

This discovery was groundbreaking because it revealed, for the first time, how the nervous system is regulated at the molecular level. NGF became the first known molecule to be involved in the growth of neurons, and its discovery opened up new avenues of research into how the nervous system develops and functions. Levi-Montalcini's work not only deepened our understanding of neurodevelopment but also shed light on how nerve cells regenerate and maintain themselves throughout life.

Impact on Neuroscience and Neurodegenerative Diseases
The discovery of NGF had far-reaching implications for the study of neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS). By understanding how NGF supports the survival and health of neurons, scientists have been able to explore new therapeutic approaches to slow or reverse the progression of these diseases. NGF has also played a pivotal role in research into nerve injury and repair, with applications in regenerative medicine that aim to restore damaged nerve tissues.

Levi-Montalcini’s work was crucial in establishing the concept of neurotrophic factors—proteins that support the growth and maintenance of neurons. Her discovery laid the foundation for a wide body of research into the molecular mechanisms underlying neurodevelopment and neuronal plasticity, processes that are fundamental to learning, memory, and the adaptation of the brain throughout life. Today, NGF remains a key focus of research in neuroscience and neurobiology.

Legacy and Honors
Throughout her illustrious career, Rita Levi-Montalcini was the recipient of numerous prestigious awards, reflecting the significance of her contributions to medical science. In 1986, she was awarded the Nobel Prize in Physiology or Medicine alongside Stanley Cohen, who helped further research on NGF. She was also honored with the National Medal of Science in 1987 by the United States, as well as numerous honorary doctorates and international recognitions.

In 2001, Levi-Montalcini was appointed as a lifetime senator in Italy, recognizing her extraordinary achievements and her dedication to advancing scientific knowledge. Throughout her later years, she remained an active advocate for scientific research and education, particularly for women in science. Her profound impact on both the scientific and broader global communities is evidenced by her tireless efforts to promote science as a tool for improving society.

Rita Levi-Montalcini’s discovery of nerve growth factor (NGF) revolutionized the field of neuroscience and has had lasting implications for the treatment of neurodegenerative diseases and neural injuries. Her resilience in the face of adversity, combined with her intellectual brilliance, made her one of the most influential figures in 20th-century medical science. Levi-Montalcini’s legacy endures through the countless lives that have been improved by her research and through the many scientists she inspired to pursue excellence in the study of the nervous system.

Detailed Introduction
Luc Montagnier was born in Chabris, France, in 1932. He pursued his education in virology and molecular biology, earning his medical degree and later taking on significant roles at research institutions such as the Pasteur Institute in Paris. Montagnier’s early research focused on various aspects of virology, particularly viral replication and the mechanisms by which viruses cause disease. However, it was his work in the early 1980s that would define his career and have far-reaching implications for global public health.

The Discovery of HIV
In the early 1980s, the world faced a rapidly growing epidemic of what would later be known as acquired immunodeficiency syndrome (AIDS). Little was understood about the disease, which was devastating communities worldwide. In 1983, while working at the Pasteur Institute, Montagnier and his team identified the virus responsible for AIDS, which they initially named lymphadenopathy-associated virus (LAV), later recognized as HIV (human immunodeficiency virus). Montagnier's discovery was based on meticulous research that isolated the virus from the lymph nodes of a patient exhibiting early symptoms of AIDS.

This discovery was groundbreaking because it provided definitive proof of the viral cause of AIDS, allowing for the development of diagnostic tests that could detect HIV infection. Montagnier’s work enabled a deeper understanding of how the virus attacked the immune system, specifically targeting CD4+ T cells, which are crucial for the body’s immune response. His research marked the beginning of global efforts to diagnose, treat, and eventually prevent the transmission of HIV.

Impact on Global Public Health
The identification of HIV transformed the medical and public health response to AIDS, turning the tide of the epidemic. By enabling the development of diagnostic tests, Montagnier’s work allowed for early detection of HIV, which became a cornerstone in controlling the spread of the virus. It also paved the way for the development of antiretroviral therapies, which have since revolutionized HIV treatment, allowing people with the virus to live longer, healthier lives. Montagnier’s contributions were crucial to the development of these therapies, as understanding the virus's lifecycle enabled scientists to target key stages in its replication process.

Beyond diagnostics and treatment, Montagnier’s discovery also played a pivotal role in the field of virology by advancing the understanding of retroviruses. His work on HIV laid the foundation for research into other viral infections and immune system disorders, contributing to the broader field of immunology.

Controversy and Later Work
While Montagnier’s discovery of HIV brought him global recognition and numerous accolades, including the Nobel Prize, his later work became more controversial. Montagnier ventured into areas of research that were considered fringe by much of the scientific community, including claims about the ability of water to retain "memory" of pathogens and theories linking HIV/AIDS to nutritional deficiencies. Despite these later controversies, his scientific achievements in the early years of his career remain indisputable.

Montagnier’s work on HIV/AIDS continued to influence the global medical community long after his Nobel Prize recognition. He remained an advocate for further research into both prevention and treatment strategies, and his early discoveries are seen as critical milestones in the battle against one of the most devastating pandemics of modern times.

Legacy and Honors
Luc Montagnier’s contributions to virology and global health were recognized with numerous prestigious awards throughout his career. In 2008, he was awarded the Nobel Prize in Physiology or Medicine alongside Françoise Barré-Sinoussi for their discovery of HIV. Montagnier’s achievements were also recognized with the Lasker Award and numerous honorary degrees from leading academic institutions worldwide.

Montagnier’s legacy is one of remarkable scientific discovery that has had a direct and lasting impact on global health. His identification of HIV fundamentally changed the way medicine approached the treatment and prevention of viral infections, and his contributions have saved millions of lives. Despite some controversies in his later career, his pioneering work in virology continues to serve as a foundation for ongoing research in the field of infectious diseases.

Luc Montagnier’s discovery of HIV was a landmark achievement in medical science, one that revolutionized the diagnosis and treatment of a global epidemic. His work remains a cornerstone of virology and immunology, and his contributions to the understanding of viral infections have had a profound and lasting impact on global health. Montagnier’s legacy is that of a scientist whose research has changed the course of modern medicine, forever shaping the global response to one of the most pressing public health challenges of the last century.

Legality

The Europäische Akademie der Medizinwissenschaften is officially registered in the United Kingdom under Registered Number 15905065, classified under SIC Code 84120, which pertains to the regulation of healthcare, education, cultural, and other social services.

Map

Here’s how you can plan a trip from London Heathrow Airport (LHR) to EAM UK Office via both driving and public transport (using the London Underground):

Driving Route

1. Start: From London Heathrow Airport, follow the signs for M4 Eastbound towards Central London.
2. Continue on the M4 for approximately 11 miles, and then merge onto the A4.
3. At Hammersmith, take the slip road onto A3220 and follow it towards Westway (A40).
4.Continue on the A40 for 6.5 miles, and take the exit onto Marylebone Road/A501.
5. After 2 miles, turn left onto City Road/A501.
6. Continue onto the A503 towards Seven Sisters Road.
7. Follow the signs to merge onto the A10 and A503.
8. Follow signs for Walthamstow, continuing onto Forest Road/A503.
9. Turn right onto St. James Street.
10. Turn left onto Brunner Road, and your destination at 76 Brunner Road, London E17 7NW will be on your right.

Driving Time: Approximately 1 hour 15 minutes, depending on traffic.

Public Transport (London Underground) Route

1. Start: From Heathrow Airport, take the Piccadilly Line (dark blue line) heading towards Cockfosters.
2. Change at Green Park Station to the Victoria Line (light blue line) heading towards Walthamstow Central.
3. Arrive at Walthamstow Central Station.
4. From Walthamstow Central, walk approximately 8 minutes along St. James Street and turn left onto Brunner Road to reach 76 Brunner Road, E17 7NW.

Public Transport Time: Approximately 1 hour 30 minutes.

Legality

The European Academy of Medical Sciences is officially recognized as a nonprofit entity in the United States, holding Confirmation Number 16304960.

Map

Here’s how you can plan a trip from San Jose, CA to the European Academy of Medical Sciences US Office located at 2381 Zanker Road, San Jose, CA, 95131, using both driving and public transportation:

Driving Route

1. Exit the airport to George Washington Memorial Parkway NORTH. Exit to Memorial Bridge.
2. Bear LEFT after crossing Memorial Bridge into Washington, DC.
3. Take second LEFT onto Henry Bacon Drive NW You must turn LEFT at this point as your route will be blocked by Jersey walls.
4. Turn RIGHT at the traffic light onto Constitution Avenue, NW.
5. Turn LEFT at second light onto 21st Street, NW.
6. Parking lot entrance is on left before traffic light at intersection with C Street NW.

By Car from Dulles International Airport

1. Start: From downtown San Jose, head north on Market Street towards W St John Street.
2. Merge onto CA-87 N via the ramp to US-101 N.
3. After about 2.5 miles, take the exit for US-101 N towards San Francisco.
4. Continue on US-101 N for approximately 3 miles.
5. Take exit 391 for Trimble Road/Zanker Road.
6. Keep right at the fork, follow signs for Zanker Road.
7. Turn left onto Zanker Road, and continue for about 1 mile.
8.Arrive at 2381 Zanker Road, San Jose, CA 95131.

Driving Time: Approximately 15-20 minutes, depending on traffic.

Public Transportation Route

1. Start: From downtown San Jose, take the VTA Light Rail from Santa Clara Station on the Green Line (G) towards Old Ironsides Station.
2. Get off at Karina Court Station.
3. From Karina Court Station, walk about 5-10 minutes north along Zanker Road.
4. Arrive at 2381 Zanker Road, San Jose, CA 95131.

Public Transport Time: Approximately 35-45 minutes, depending on schedule.